


## FINLAND

Pharmaceuticals Pricing Board  
 Jaana Martikainen  
 email: jaana.martikainen@stm.fi  
 phone: +358 476 1898



### Pharmaceutical pricing and reimbursement policies in the in- and out-patient sector

#### OUT-PATIENT

#### IN-PATIENT

##### Competent authorities

**Pharmaceuticals Pricing Board** (subordinated to the Ministry of Social Affairs and Health) confirms reimbursement status and a wholesale price of medicinal products, clinical nutritional preparations and basic ointments that are reimbursable by the Health Insurance Act.

**Social Insurance Institution (Kela)** administers the drug reimbursement system.

##### Competent authorities

Hospital districts owned by municipalities.

Procurement is typically done by procurement pools (e.g. responsibility areas of university hospitals).

##### Pricing

Non-reimbursable pharmaceuticals can be priced freely.

##### **Statutory pricing (at wholesale price level) for reimbursable pharmaceuticals.**

Pricing procedures include:

- External price referencing
- Internal price referencing
- Health economic evaluations

For generics: price linkage, generic substitution and reference pricing (RPS)

For biosimilars: price linkage

Decisions valid max 5 years; for new active substance max 3 years.

**Wholesale remuneration:** Not controlled

**Pharmacy remuneration:** Statutory regressive mark-up separately for prescription and non-prescription pharmaceuticals

**VAT:** Standard rate 24%, reduced rate for medicines 10%

##### **Reforms valid from Jan 2017:**

- wholesale price of the 1<sup>st</sup> biosimilar must be at least 30% lower than price of the originator.
- RPS: extended to parallel imported products, "price corridor" narrowed to €0.50.
- Managed-entry agreements (MEA) allowed (temporary legislation valid until end of 2019; new proposal: until end of 2025).


##### Pricing

Price negotiations or tendering of pharmaceuticals.

Each hospital has its own pharmaceutical formulary.

PRICING

##### Reimbursement



**Reference price system (RPS):** Generic reference price groups: same active substance, quantity and pharmaceutical form, closely corresponding package size

**Mechanisms for vulnerable groups:** Better reimbursement rate for pharmaceuticals used for chronic and severe diseases (Special reimbursements)

##### **Recent reforms**

- Reimbursement rate of type II antidiabetics (A10B) reduced from 100% to 65%.
- Annual co-payment ceiling lowered from €608 to €572.

##### Reimbursement

Hospital pharmacies issue medicines only to their own wards and departments.

Pharmaceuticals used in hospitals are included in the patient's daily charge.

REIMBURSEMENT